(vianews) - shares of medincell (cac 40: medcl.pa) dropped by a staggering 20.61% in 10 sessions from €8.88 to €7.05 at 02:06 est on monday, after five successive sessions in a row of losses. cac 40 is rising 0.45% to €7,414.85, after two successive sessions in a row of gains.
medincell's last close was €7.05, 32.86% under its 52-week high of €10.50.
about medincell
medincell s.a. develops various therapeutic solutions in france. it develops solutions based on bepo, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. the company's products in development include mdc-irm, a risperidone extended-release injectable suspension completed phase iii trial for use in the treatment of schizophrenia; mdc-cwm, a sustained-release formulation of celecoxib in phase iii trials for use in the treatment of reduction of postoperative pain & inflammation; and mdc-tjk, a subcutaneous injection in phase iii trials for use in the treatment of schizophrenia. its product candidates in preclinical trials, such as mdc-ang, an antipsychotic product for use in the treatment of schizophrenia; mdc-ttg for covid-19 and its variants; mdc-grt for use in organ transplant; mdc-wwm for contraception; mdc-stm for use in malaria; mdc-kpt for use in acute pain for pets; and mdc-irm for use in neuroscience. the company was incorporated in 2003 and is based in jacou, france.
earnings per share
as for profitability, medincell has a trailing twelve months eps of €-0.97.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, medincell's stock is considered to be overbought (>=80).
yearly top and bottom value
medincell's stock is valued at €7.05 at 02:06 est, way under its 52-week high of €10.50 and way higher than its 52-week low of €4.73.
volume
today's last reported volume for medincell is 462954 which is 377.65% above its average volume of 63456.
more news about medincell (medcl.pa).